乳腺癌组织中DNA修复酶MGMT、XRCC1的表达与临床预后因素的关系

DNA repair enzymes O6-methylguanine-DNA methytransferase and X-ray repair cross complementing 1 and the clinical prognostic factors in breast cancer

目的 探讨乳腺癌组织中O6-甲基鸟嘌呤-DNA-甲基转移酶（MGMT）和X线修复交叉互补基因1（XRCC1）的表达及与临床预后因素的关系.方法 采用SP免疫组织化学法检测110例乳腺癌石蜡标本、19例纤维腺瘤石蜡标本及11例正常乳腺组织石蜡标本中MGMT和XRCC1蛋白的表达,分析其与临床预后因素的关系.结果 110例乳腺癌组织中MGMT阳性表达率为71.8%,其表达与乳腺癌患者的病理类型、浸润性导管癌的病理分化程度、淋巴结是否转移及ER表达明显相关（P＜0.05）.XRCC1阳性表达率为30.9%,其表达与患者的肿瘤大小、浸润性导管癌的病理分化程度明显相关（P＜0.05）.此外,MGMT与XRCC1的表达明显相关（P＜0.05）,生存分析表明MGMT、XRCC1是影响生存期的因素（P＜0.05）.结论 DNA修复基因MCMT及XRCC1是临床评估乳腺癌恶性程度、判断预后及制定治疗策略的病理指标之一.

Objective To investigate the expression of O6-methylguanine-DNA methytransferase （MGMT） and X-ray repair cross complementing 1 （XRCC1） in breast cancer, and their relationship with clinical prognostic factors. Methods Immunohistochemistry （S-P） was performed for MGMT and XRCC1 on 110 specimens of breast cancer, 19 specimens of fibroadenoma and 11 specimens of normal breast tissues. Results The positive expression rate of MGMT was 71.8%, which had a correlation with pathological classification, pathological grades of infitrating ductal carcinoma （ IDG）, axillas lymph nodes metastasis, and expression of ER （ P 〈 0.05）. The positive expression rate of XRCC1 was 30.9%, which had a correlation with the tumor size and the pathological grades of IDG. The expression rate of MGMT had a positive correlation with XRCC1 （P 〈0.05）. The survival analysis showed that MGMT and XRCC1 may be considered a independent maker in breast cancer （ P 〈 0.05 ）. Conclusion MGMT and XRCC1 were important pathological signs to evaluate the malignancy degree and prognosis of the breast cancer. These markers play an important role in working out the treatment prescription for breast cancer patients.